《中国康复理论与实践》 ›› 2019, Vol. 25 ›› Issue (7): 778-782.doi: 10.3969/j.issn.1006-9771.2019.07.007
李策, 张备, 白玉龙
收稿日期:2018-10-04
修回日期:2018-11-26
出版日期:2019-07-25
发布日期:2019-07-23
通讯作者:
白玉龙
E-mail:dr_baiyl@fudan.edu.cn
作者简介:李策(1988-),女,汉族,河北保定市人,博士研究生,主要研究方向:脑卒中后的康复机制及基础研究。
基金资助:LI Ce, ZHANG Bei, BAI Yu-long
Received:2018-10-04
Revised:2018-11-26
Published:2019-07-25
Online:2019-07-23
Contact:
BAI Yu-long
E-mail:dr_baiyl@fudan.edu.cn
Supported by:摘要: 以往5-羟色胺再摄取抑制剂(SSRIs)被广泛应用于改善脑卒中后抑郁,近年来SSRIs被认为是改善缺血性脑卒中后运动功能障碍的有效药物。目前关于SSRIs改善脑缺血后运动功能的机制研究内容较广泛,尚无统一结论;SSRIs能否确切改善脑缺血后运动功能存在矛盾的观点,且SSRIs应用于脑卒中治疗存在潜在风险。应有效评估SSRIs应用的收益与风险。
中图分类号:
李策, 张备, 白玉龙. 5-羟色胺再摄取抑制剂在缺血性脑卒中中的应用及机制研究进展[J]. 《中国康复理论与实践》, 2019, 25(7): 778-782.
LI Ce, ZHANG Bei, BAI Yu-long. Advance in Clinial and Mechanism Reseaches about Serotonin Selective Reuptake Inhibitors for Ischemic Stroke (review)[J]. 《Chinese Journal of Rehabilitation Theory and Practice》, 2019, 25(7): 778-782.
| 1 de KeyserJ, SulterG, LuitenP G. Clinical trials with neuroprotective drugs in acute ischaemic stroke: are we doing the right thing? [J]. Trends Neurosci, 1999, 22(12): 535-540. 2 ChenH F, PanX L, WangJ W, et al. Protein-drug interactome analysis of SSRI-mediated neurorecovery following stroke [J]. Biosystems, 2014, 120: 1-9. 3 RueterL E, FornalC A, JacobsB L. A critical review of 5-HT brain microdialysis and behavior [J]. Rev Neurosci, 1997, 8(2): 117-137. 4 MostertJ P, KochM W, HeeringsM, et al. Therapeutic potential of fluoxetine in neurological disorders [J]. Cns Neurosci Ther, 2008, 14(2): 153-164. 5 HackettM L, PicklesK. Part I: frequency of depression after stroke: an updated systematic review and meta-analysis of observational studies [J]. Int J Stroke, 2014, 9(8): 1017-1025. 6 FlasterM, SharmaA, RaoM. Poststroke depression: a review emphasizing the role of prophylactic treatment and synergy with treatment for motor recovery [J]. Top Stroke Rehabil, 2013, 20(2): 139-150. 7 ParienteJ, LoubinouxI, CarelC, et al. Fluoxetine modulates motor performance and cerebral activation of patients recovering from stroke [J]. Ann Neurol, 2001, 50(6): 718-729. 8 PaolucciS, AntonucciG, GrassoM G, et al. Post-stroke depression, antidepressant treatment and rehabilitation results. A case-control study [J]. Cerebrovasc Dis, 2001, 12(3): 264-271. 9 CholletF, TardyJ, AlbucherJ F, et al. Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial [J]. Lancet Neurol, 2011, 10(2): 123-130. 10 MeadG E, HsiehC F, LeeR, et al. Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery [J]. Cochrane Database Syst Rev, 2012, 11: CD009286. 11 RobinsonR G, SchultzS K, CastilloC, et al. Nortriptyline versus fluoxetine in the treatment of depression and in short-term recovery after stroke: a placebo-controlled, double-blind study [J]. Am J Psychiatry, 2000, 157(3): 351-359. 12 PlegerB, SchwenkreisP, GrunbergC, et al. Fluoxetine facilitates use-dependent excitability of human primary motor cortex [J]. Clin Neurophysiol, 2004, 115(9): 2157-2163. 13 NannettiL, PaciM, PasquiniJ, et al. Motor and functional recovery in patients with post-stroke depression [J]. Disabil Rehabil, 2005, 27(4): 170-175. 14 GonzenbachR R, TaegtmeyerA B, LuftA, et al. Fluoxetine and motor recovery after ischaemic stroke [J]. Lancet Neurol, 2011, 10(6): 499-500. 15 ShinT K, KangM S, LeeH Y, et al. Fluoxetine and sertraline attenuate postischemic brain injury in mice [J]. Korean J Physiol Pharmacol, 2009, 13(3): 257-263. 16 LimC M, KimS W, ParkJ Y, et al. Fluoxetine affords robust neuroprotection in the postischemic brain via its anti-inflammatory effect [J]. J Neurosci Res, 2009, 87(4): 1037-1045. 17 NgK L, GibsonE M, HubbardR, et al. Fluoxetine maintains a state of heightened responsiveness to motor training early after stroke in a mouse model [J]. Stroke, 2015, 46(10): 2951-2960. 18 ZhuB G, SunY, SunZ Q, et al. Optimal dosages of fluoxetine in the treatment of hypoxic brain injury induced by 3-nitropropionic acid: implications for the adjunctive treatment of patients after acute ischemic stroke [J]. CNS Neurosci Ther, 2012, 18(7): 530-535. 19 LoubinouxI, TombariD, ParienteJ, et al. Modulation of behavior and cortical motor activity in healthy subjects by a chronic administration of a serotonin enhancer [J]. Neuroimage, 2005, 27(2): 299-313. 20 Gerdelat-MasA, LoubinouxI, TombariD, et al. Chronic administration of selective serotonin reuptake inhibitor (SSRI) paroxetine modulates human motor cortex excitability in healthy subjects [J]. Neuroimage, 2005, 27(2): 314-322. 21 BerendsH I, NijlantJ, van PuttenM, et al. Single dose of fluoxetine increases muscle activation in chronic stroke patients [J]. Clin Neuropharmacol, 2009, 32(1): 1-5. 22 QiaoJ, WangJ, WangH, et al. Regulation of astrocyte pathology by fluoxetine prevents the deterioration of Alzheimer phenotypes in an APP/PS1 mouse model [J]. Glia, 2016, 64(2): 240-254. 23 ShanH, BianY, ShuZ, et al. Fluoxetine protects against IL-1beta-induced neuronal apoptosis via downregulation of p53 [J]. Neuropharmacology, 2016, 107: 68-78. 24 SiepmannT, PenzlinA I, KepplingerJ, et al. Selective serotonin reuptake inhibitors to improve outcome in acute ischemic stroke: possible mechanisms and clinical evidence [J]. Brain Behav, 2015, 5(10): e00373. 25 TiradentesR V, PiresJ G, SilvaN F, et al. Effects of acute administration of selective serotonin reuptake inhibitors on sympathetic nerve activity [J]. Braz J Med Biol Res, 2014, 47(7): 554-559. 26 GreeneJ, BanasrM, LeeB, et al. Vascular endothelial growth factor signaling is required for the behavioral actions of antidepressant treatment: pharmacological and cellular characterization [J]. Neuropsychopharmacology, 2009, 34(11): 2459-2468. 27 TakebayashiM, HashimotoR, HisaokaK, et al. Plasma levels of vascular endothelial growth factor and fibroblast growth factor 2 in patients with major depressive disorders [J]. J Neural Transm (Vienna), 2010, 117(9): 1119-1122. 28 SchmidtH D, DumanR S. The role of neurotrophic factors in adult hippocampal neurogenesis, antidepressant treatments and animal models of depressive-like behavior [J]. Behav Pharmacol, 2007, 18(5-6): 391-418. 29 DempseyR J, SailorK A, BowenK K, et al. Stroke-induced progenitor cell proliferation in adult spontaneously hypertensive rat brain: effect of exogenous IGF-1 and GDNF [J]. J Neurochem, 2003, 87(3): 586-597. 30 WiltroutC, LangB, YanY, et al. Repairing brain after stroke: a review on post-ischemic neurogenesis [J]. Neurochem Int, 2007, 50(7-8): 1028-1041. 31 TiraboschiE, TarditoD, KasaharaJ, et al. Selective phosphorylation of nuclear CREB by fluoxetine is linked to activation of CaM kinase IV and MAP kinase cascades [J]. Neuropsychopharmacology, 2004, 29(10): 1831-1840. 32 LonzeB E, GintyD D. Function and regulation of CREB family transcription factors in the nervous system [J]. Neuron, 2002, 35(4): 605-623. 33 MercierG, LennonA M, RenoufB, et al. MAP kinase activation by fluoxetine and its relation to gene expression in cultured rat astrocytes [J]. J Mol Neurosci, 2004, 24(2): 207-216. 34 RiefW, BarskyA J, BingelU, et al. Rethinking psychopharmacotherapy: the role of treatment context and brain plasticity in antidepressant and antipsychotic interventions [J]. Neurosci Biobehav Rev, 2016, 60: 51-64. 35 OfekK, SchoknechtK, Melamed-BookN, et al. Fluoxetine induces vasodilatation of cerebral arterioles by co-modulating NO/muscarinic signalling [J]. J Cell Mol Med, 2012, 16(11): 2736-2744. 36 KhodanovichM, KiselA, KudabaevaM, et al. Effects of fluoxetine on hippocampal neurogenesis and neuroprotection in the model of global cerebral ischemia in rats [J]. Int J Mol Sci, 2018. DOI: info:doi/10.3390/ijms19010162. 37 SinghD P, ChopraK. Flavocoxid, dual inhibitor of cyclooxygenase-2 and 5-lipoxygenase, exhibits neuroprotection in rat model of ischaemic stroke [J]. Pharmacol Biochem Behav, 2014, 120: 33-42. 38 DhamiK S, ChurchwardM A, BakerG B, et al. Fluoxetine and citalopram decrease microglial release of glutamate and D-serine to promote cortical neuronal viability following ischemic insult [J]. Mol Cell Neurosci, 2013, 56: 365-374. 39 LiW L, CaiH H, WangB, et al. Chronic fluoxetine treatment improves ischemia-induced spatial cognitive deficits through increasing hippocampal neurogenesis after stroke [J]. J Neurosci Res, 2009, 87(1): 112-122. 40 ArvidssonA, CollinT, KirikD, et al. Neuronal replacement from endogenous precursors in the adult brain after stroke [J]. Nat Med, 2002, 8(9): 963-970. 41 VaswaniM, LindaF K, RameshS. Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review [J]. Prog Neuropsychopharmacol Biol Psychiatry, 2003, 27(1): 85-102. 42 SunX, SunX, LiuT, et al. Fluoxetine enhanced neurogenesis is not translated to functional outcome in stroke rats [J]. Neurosci Lett, 2015, 603: 31-36. 43 OhabJ J, FlemingS, BleschA, et al. A neurovascular niche for neurogenesis after stroke [J]. J Neurosci, 2006, 26(50): 13007-13016. 44 SunY, SunX, QuH, et al. Neuroplasticity and behavioral effects of fluoxetine after experimental stroke [J]. Restor Neurol Neurosci, 2017, 35(5): 457-468. 45 CorbettA M, SieberS, WyattN, et al. Increasing neurogenesis with fluoxetine, simvastatin and ascorbic acid leads to functional recovery in ischemic stroke [J]. Recent Pat Drug Deliv Formul, 2015, 9(2): 158-166. 46 PengL, GuL, LiB, et al. Fluoxetine and all other SSRIs are 5-HT2B agonists - Importance for their therapeutic effects [J]. Curr Neuropharmacol, 2014, 12(4): 365-379. 47 HertzL, RothmanD L, LiB, et al. Chronic SSRI stimulation of astrocytic 5-HT2B receptors change multiple gene expressions/editings and metabolism of glutamate, glucose and glycogen: a potential paradigm shift [J]. Front Behav Neurosci, 2015, 9: 25. 48 DiazS L, Narboux-NemeN, BoutourlinskyK, et al. Mice lacking the serotonin 5-HT2B receptor as an animal model of resistance to selective serotonin reuptake inhibitors antidepressants [J]. Eur Neuropsychopharmacol, 2016, 26(2): 265-279. 49 WindleV, CorbettD. Fluoxetine and recovery of motor function after focal ischemia in rats [J]. Brain Res, 2005, 1044(1): 25-32. 50 ZhaoC S, PuurunenK, SchallertT, et al. Behavioral and histological effects of chronic antipsychotic and antidepressant drug treatment in aged rats with focal ischemic brain injury [J]. Behav Brain Res, 2005, 158(2): 211-220. 51 WangM T, ChuC L, YehC B, et al. Antidepressant use and risk of recurrent stroke: a population-based nested case-control study [J]. J Clin Psychiatry, 2015, 76(7): e877-e885. 52 HeY, CaiZ, ZengS, et al. Effect of fluoxetine on three-year recurrence in acute ischemic stroke: a randomized controlled clinical study [J]. Clin Neurol Neurosurg, 2018, 168: 1-6. 53 MortensenJ K, LarssonH, JohnsenS P, et al. Post stroke use of selective serotonin reuptake inhibitors and clinical outcome among patients with ischemic stroke: a nationwide propensity score-matched follow-up study [J]. Stroke, 2013, 44(2): 420-426. 54 PintoC B, Saleh VelezF G, LopesF, et al. SSRI and motor recovery in stroke: reestablishment of inhibitory neural network tonus [J]. Front Neurosci, 2017, 11: 637. 55 AlperK, SchwartzK A, KoltsR L, et al. Seizure incidence in psychopharmacological clinical trials: an analysis of Food and Drug Administration (FDA) summary basis of approval reports [J]. Biol Psychiatry, 2007, 62(4): 345-354. 56 LiepertJ. Update on pharmacotherapy for stroke and traumatic brain injury recovery during rehabilitation [J]. Curr Opin Neurol, 2016, 29(6): 700-705. 57 FoltinR W, HaneyM, ComerS D, et al. Effect of fluoxetine on food intake of humans living in a residential laboratory [J]. Appetite, 1996, 27(2): 165-181. 58 RieckmannN, KronishI M, ShapiroP A, et al. Serotonin reuptake inhibitor use, depression, and long-term outcomes after an acute coronary syndrome: a prospective cohort study [J]. JAMA Intern Med, 2013, 173(12): 1150-1151. 59 GrahamC, LewisS, ForbesJ, et al. The FOCUS, AFFINITY and EFFECTS trials studying the effect(s) of fluoxetine in patients with a recent stroke: statistical and health economic analysis plan for the trials and for the individual patient data meta-analysis [J]. Trials, 2017, 18(1): 627. |
| [1] | 吴澄, 章云枫, 王卫宁, 余克威, 张艳正, 沈嘉蓉, 吴毅. 肘腕功能支具对脑卒中偏瘫患者足底压力和平衡功能的效果[J]. 《中国康复理论与实践》, 2026, 32(1): 30-39. |
| [2] | 高云汉, 侯闪闪, 汪鑫煜, 朱崇田. 基于功能性近红外光谱探讨脑机接口对脑卒中患者上肢运动功能障碍的效果[J]. 《中国康复理论与实践》, 2025, 31(9): 1066-1073. |
| [3] | 杨同念, 任杰, 肖辉. 儿童青少年身体活动对焦虑的效果:系统综述的系统综述[J]. 《中国康复理论与实践》, 2025, 31(8): 883-888. |
| [4] | 叶绿, 陈悦琳, 刘雨霏. 儿童身体活动与脑健康的认知神经科学研究技术范式与进展:Scoping综述[J]. 《中国康复理论与实践》, 2025, 31(8): 889-895. |
| [5] | 王晓锋, 胡梦巧, 汪嫣, 魏坤, 徐文竹, 任丹, 马晔. 外骨骼机器人辅助步态训练对脑卒中和脊髓损伤下肢功能康复效果的系统综述[J]. 《中国康复理论与实践》, 2025, 31(8): 914-921. |
| [6] | 顾逸青, 程舒芃, 李勇强, 毛二莉, 励建安. 成年气管切开患者拔管的直接策略与堵管策略对比的系统综述[J]. 《中国康复理论与实践》, 2025, 31(6): 666-673. |
| [7] | 吴晓晖, 蒋雷, 朱静茹, 解利辉. 深度学习在老年人轻度认知障碍诊断中应用的Scoping综述[J]. 《中国康复理论与实践》, 2025, 31(6): 674-681. |
| [8] | 刘璇, 高玲, 褚凤明, 陈杰, 张明. 脑机接口联合上肢康复机器人对脑卒中患者上肢功能的影响[J]. 《中国康复理论与实践》, 2025, 31(6): 703-710. |
| [9] | 周天添, 张通, 张琦, 梁艳华, 张燕庆, 岳青, 李思佳. Lokomat机器人辅助步行训练对偏瘫儿童下肢运动功能的效果[J]. 《中国康复理论与实践》, 2025, 31(6): 711-720. |
| [10] | 邹聪聪, 王潇珺, 马锦蓉, 鲁商波, 丁勇, 王哈妮, 宋建飞. 耳迷走神经电刺激联合双任务训练对缺血性脑卒中患者上肢功能的效果[J]. 《中国康复理论与实践》, 2025, 31(5): 513-519. |
| [11] | 潘义, 厚双龙, 温晓妮. 经皮迷走神经刺激在成年人执行功能中应用的Scoping综述[J]. 《中国康复理论与实践》, 2025, 31(5): 520-528. |
| [12] | 王梅, 朱文平. 身体活动干预2型糖尿病患者的健康效益:系统综述的系统综述[J]. 《中国康复理论与实践》, 2025, 31(5): 553-560. |
| [13] | 施滨, 徐宁, 周广雪. 镜像疗法应用于脑卒中运动功能康复的文献计量分析[J]. 《中国康复理论与实践》, 2025, 31(5): 561-572. |
| [14] | 叶绿, 常晶, 凌海润. 网络行为成瘾的运动干预效果:系统综述的系统综述[J]. 《中国康复理论与实践》, 2025, 31(4): 431-440. |
| [15] | 李鑫磊, 魏伟, 宋健, 赵雨晴, 孔维橙, 蔡嘉玉, 施浩然, 薛偕华. 静息态脑电图在脑卒中患者上肢运动功能评估中的应用[J]. 《中国康复理论与实践》, 2025, 31(4): 448-457. |
| 阅读次数 | ||||||
|
全文 |
|
|||||
|
摘要 |
|
|||||
|
||